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Abstract
Introduction
The goals of this study were to determine U.S. states
with Comprehensive Cancer Control plans that include
genomics in some capacity and to review successes with
and barriers to implementation of genomics-related cancer
control initiatives.
Methods
This study was conducted in two phases. Phase one
included a content analysis of written state
Comprehensive Cancer Control plans (n = 30) for terms
related to genomics, or “genomic components” (n = 18). The
second phase involved telephone interviews with the
Comprehensive Cancer Control plan coordinators in states
with plans that contained genomic components (n = 16).
The interview was designed to gather more detailed infor-
mation about the genomics-related initiatives within the
state’s Comprehensive Cancer Control plan and the suc-
cesses with and barriers to plan implementation, as
defined by each state.
Results
Eighteen of the 30 Comprehensive Cancer Control plans
analyzed contained genomics components. We noted a
large variability among these 18 plans in the types of
genomics components included. Nine (56%) of the 16 states
interviewed had begun to implement the genomics compo-
nents in their plan. Most states emphasized educating
health care providers and the public about the role of
genomics in cancer control. Many states consider aware-
ness of family history to be an important aspect of their
Comprehensive Cancer Control plan. Approximately 67%
of states with family history components in their plans had
begun to implement these goals. Virtually all states
reported they would benefit from additional training in
cancer genetics and general public health genomics.
Conclusion
The number of states incorporating genomics into their
Comprehensive Cancer Control plans is increasing.
Family history is a public health application of genomics
that could be implemented more fully into Comprehensive
Cancer Control plans.
Introduction
Comprehensive Cancer Control (CCC) is an emerging
public health model that seeks to bring together public and
private stakeholders to efficiently use limited resources to
reduce the burden of cancer. The CCC program allows
states and territories to facilitate their own partnerships
to address their unique cancer burdens. CCC results in
many benefits, including increased efficiency for delivering
public health messages and services to the public. The
Centers for Disease Control and Prevention’s (CDC’s)
National CCC Program (NCCCP) is a resource for sup-
porting CCC efforts. Since 1998, the number of programs
participating in NCCCP has grown from six to 61 (1). With
this support, state, tribal, and territorial health agencies
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continue to establish broad-based CCC coalitions, to assess
the burden of cancer, to determine priorities for cancer
prevention and control, and to develop and implement
CCC plans. State planners play a large and important role
in CCC programs as the cancer burden increases for the
population and advances in cancer genomics continue to
challenge public health specialists.
For public health purposes, genetics may be defined as
the “study of single gene hereditability,” whereas genomics
is the study of functions and interactions of all the genes
in the genome, including their interactions with environ-
mental factors (2). It is estimated that 5% to 10% of cancer
is caused by autosomal dominant inherited genetic
changes, such as BRCA1 and BRCA2 mutations in breast
and ovarian cancer (3). Family history of cancer in a first-
degree relative has been shown to confer an increased can-
cer risk (e.g., the relative risk of breast cancer conferred by
a first-degree relative with breast cancer is 2.1) (4).
Individuals who may have a genetic susceptibility because
of cancer in their family can be distinguished from indi-
viduals in the general population by the relatively
straightforward process of taking a family history. The
American Society of Clinical Oncology supports integrat-
ing cancer risk assessment and management, including
genetic testing for cancer predisposition genes, into the
practice of oncology and preventive medicine (5).
The states are committed to reducing the burden of can-
cer among their populations, and the emerging contribu-
tion of genetics and genomics to the field of cancer control
cannot be ignored. The goals of this study were to deter-
mine U.S. states that include genomics in some capacity in
their CCC plans and to review the successes with and bar-
riers to implementation of these genomics-related state
cancer control initiatives.
Methods
This study was conducted in two phases. The first phase
was a content review of written state cancer control plans.
In collaboration with the CDC, the North Carolina Center
for Genomics and Public Health (NCCGPH) identified
state CCC plans funded by the CDC from 1997 to 2004.
Each plan was searched for the words “genetics,”
“genomics,” “genes,” “family history,” “DNA,” “first-degree
relative,” and “heritability.” The search terms were identi-
cal to those chosen by the CDC for an earlier content
analysis. These search terms were used to create a com-
prehensive list of potential genomics-related topics found
within the state plans. Throughout this document, these
terms will be referred to as “genomic components.”
Several themes from among the genomic components
were detected across plans, and these were tabulated. A
report was written summarizing overall themes, sup-
plying standardized definitions of genomic components,
and detailing genomic components found in each state’s
CCC plan.
Once the written CCC plans were reviewed, five topic
areas were identified as areas needing more information to
provide a more complete picture of the genomic compo-
nents within the plans. The five topic areas were 1) the
CCC plan writing process; 2) successes with and barriers
to implementation; 3) general public and health care
provider education programs that may have been 
implemented; 4) priority of genomics in the state health
department; and 5) additional partnerships, training, and
technical assistance that would be useful for CCC coordi-
nators, coalitions, and state cancer control planners.
NCCGPH staff, in consultation with the CDC, developed a
telephone interview to gather additional information on
these topics. The Institutional Review Board of the
University of North Carolina approved the interview com-
ponent of the study.
The second phase of the study involved telephone inter-
views with the CCC plan coordinators in states with
genomic components in their cancer control plans. Sixteen
of the 18 states agreed to be interviewed. The summary
report from the content review of the written CCC plans
(Phase 1) was sent to all 16 of the state CCC coordinators
for their review prior to their scheduled interview. At the
beginning of the interview, the CCC coordinators were
asked to verify that the summary of genomic components
for their state was accurate and complete. No changes or
additions were made by any of the states interviewed. All
interviews were audiotaped and transcribed, and copies of
the transcriptions were sent back to each state for quality
control purposes and their final approval.
The interview used a semistructured questionnaire
(Appendix) and gathered information about only the
genomic components within the CCC plan. (The other ele-
ments of the CCC plans were not discussed in the inter-
view.) The questions addressed the five topics listed above.
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the “genomic components” had begun based on the context
of their state plan. In addition, standardized definitions of
“success and barriers” were not imposed; each state was
allowed to determine success based on its plan and goals.
Results
Summary of written Comprehensive Cancer Control plans
Of the 30 CCC plans analyzed, 18 contained genomic
components. Among these 18 plans, we found large vari-
ability in the types of genomic components included. Table
1 summarizes the frequency of the main themes among
the CCC plans. Most states used the terms “genetics” or
“family history,” while only one state referred to
“genomics” in the written CCC plan. Half of the states
intended to monitor advances in the cancer genomics field
by publishing new information through their in-house
newsletters, convening advisory panels, working with
statewide experts in the field, and providing professional
educational programs. Slightly more than one quarter of
the states discussed gene–environment interactions in any
context. Gene–environment interactions were discussed
under a variety of topics; for example, variations seen in
incidence rates among racial and ethnic groups for certain
cancers, genetic research studies on various nutrients, and
the relationship between inherited susceptibility and envi-
ronmental factors for some cancers.
One theme, education, consistently presented itself in
two forms: 1) increasing awareness about genomics among
health care providers, and 2) providing education about
genomics and its role in cancer control to patients and the
general public. Approximately 44% of the CCC plans tar-
geted education of health care providers and the public to
promote early screening for those individuals identified at
higher risk of cancer based on family history (data not
shown). Also, one third of plans (33%) mentioned training
health care professionals in the use of cancer risk assess-
ment, including the use of family history tools.
Summary of interviews
Nine out of the 16 states interviewed had begun imple-
mentation of the genomic components of their plan at the
time of our interview (Table 2). All of these states were
funded through implementation-type grants. States that
reported initiation of implementation projects did so large-
ly through educational forums or seminars, presentations
at professional meetings, publication and distribution of
fact sheets on specific cancers, and public service
announcements (PSAs) that included issues of family his-
tory. Only two states reported that genomics was some-
what not a priority within their state health department
(Table 2). Many states (43.7%) reported implementing
education efforts aimed at health care providers, and 25%
of the states reported providing some form of public edu-
cation about genomics. Educational efforts have been
accomplished mainly through holding open meetings and
seminars, attending public health fairs, publishing fact
sheets, issuing PSAs, and developing Web sites (Table 2).
Six states (data not shown) discussed implementation
of their objectives to educate the public about family his-
tory. Initiatives included developing fact sheets,
brochures, and Web sites discussing individual cancers
and the role that family history plays as an important
risk factor to consider when assessing cancer risk and
the need for early screening. Some of these states held
forums for health care professionals to discuss the
importance of family history as a tool in assessing can-
cer risk. One state has convened a panel and developed
a pilot to use the state cancer registry to help identify
families at high risk for cancer development.
The primary reasons cited for successful implementation
of genomic components within the state CCC plans were
the following: 1) establishing strong partnerships within
the state; 2) obtaining additional funding for implementa-
tion; and 3) making genomics a high priority within the
state health department (Table 3). The types of partner-
ships varied and included private industry, major medical
centers within the state, public research institutions, and
universities. Many of the advisory committees had mem-
bers who convened an array of partners within the state.
Funding was obtained from national and local organiza-
tions, private industry, academic institutions, and other
public resources. As expected, lack of additional funding
and competing priorities were the major reasons cited as
barriers to successful implementation (Table 3).
Virtually all of the states interviewed indicated that
they would welcome additional training (n = 14) and/or
technical assistance (n = 6) in genomics. States requesting
additional training preferred some level of interpersonal
interaction (100%), with the essential component being a
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live person to field questions, whether that be via phone,
video, the Internet, or a face-to-face training session.
A basic public health genomics course was requested by
12 states, with topics including 1) the definition of genet-
ics vs genomics; 2) risk assessment and family history
issues; 3) proteomics; and 4) gene–environment interac-
tion (Table 4). Three states requested training in the ethi-
cal, legal, and social issues (ELSI) of cancer genomics
(Table 4). And six states requested a template or “how to”
guide for implementing genomics issues into cancer con-
trol (Table 4). In addition to training requests, six states
requested technical assistance; five of these six states
requested program planning, implementation, and evalu-
ation services (Table 4).
Discussion
As expected, we noted a great deal of inconsistency in
both the overall content and the level of detail within spe-
cific action plans. It is important to note that the dates
and coverage of the plans range from 1997 to 2008. The
more recently published plans have more extensive
genomics content. For example, early plans (published in
1997 or 1998) do not include a section on breast cancer
and genetic testing for susceptibility. The primary
genomic components within these earlier plans are relat-
ed to family history as a cancer risk factor. Conversely,
plans published after 2000 provide more information on
genetic testing for inherited breast cancer susceptibility
(BRCA1 and BRCA2 genes) as well as brief discussions of
familial risk assessment.
Individuals involved in writing the plans and the
process that each state underwent to write the plans may
also have contributed to the variability in genomic 
components seen among the CCC plans. Some of the indi-
viduals interviewed for this review were not on staff at
the time the plans were written and could only provide
limited information regarding the process. However, all of
the states used a collaborative writing process, involving 
several individuals with varying expertise who came
together to draft the plans. In addition, the individuals
interviewed may not be aware of all the programs that are
ongoing within their state, so these results may reflect a
subset of genomics-related activities within the state
health department.
Nine of the 16 states we interviewed had begun to imple-
ment genomics-related projects within their CCC plan.
Implementation was not strictly defined for the states, but
instead states were allowed to determine whether or not
implementation had begun based on the context of their
state plan. The states were given the opportunity to define
“successful” for the context of their program. Similarly, a
standardized definition of “success and barriers” was not
imposed. Hence, there is most likely variability in the
interpretation of these terms.
Some of the state implementation projects were specifi-
cally designed to address genomics-related goals and
objectives within the CCC plan, while other states have
chosen to implement broader programs to address
genomics-related CCC components as well as other CCC
plan goals. These implementation projects varied greatly
among the states and included such activities as creating
Web sites and fact sheets and developing innovative pub-
lic and health care provider educational programs. For
example, one state trained local barbers in an ethnic com-
munity as “lay educators” to promote prostate cancer
awareness, including risk from family history. Using the
barbershop as a gathering place, the lay educators provid-
ed literature and information to clientele about the impor-
tance of early screening and family history risk. A video
was also created to play in the barbershop to provide more
information about prostate cancer.
It is interesting to note that only one of the plans
reviewed actually used the term “genomics”; the others
used the term “genetics.” The one plan that used the term
“genomics” was recently updated, reflecting the fact that
genomics is a relatively new concept. The understanding
of and use of this term may not yet be fully incorporated
into public health practice. In addition, because
“genomics” is new terminology, some states may have
chosen not to use the term in order to make their plans
more reader friendly.
Education is a theme that consistently presented itself
in two forms: 1) increasing awareness about genomics
among legislators and health care providers, and 2) pro-
viding education about genomics and its role in cancer con-
trol to patients, providers, and the general public. All of
the plans discuss educating the public about early screen-
ing and prevention, specifically for breast, ovarian, colon,
and prostate cancers. Most plans discuss the emerging
field of cancer genetics, and all of the plans mention the
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field. Educational programs were implemented as part of
ongoing seminars or as stand-alone events, including
fairs, athletic events, and social hours. Their success
was reported as being largely dependent on aspects of
their presentation (appropriate topics, dynamic speak-
ers), timing (appropriate length for the event) and 
successful advertising.
The emphasis placed on raising awareness and edu-
cating health care providers and the public may reflect
the time at which the plans were written, which was still
early in the process of integrating genetics into public
health cancer control efforts. This result seems appro-
priate given the early stages of the field of cancer
genomics and available public health applications at the
time of publication. Also, there were few commercially
available tests for cancer genes that showed a signifi-
cant public health benefit at the time these state plans
were developed.
Using family history as a risk assessment tool is an
important component within cancer genetics and one of
the most amenable public health applications of genomics
at this time (5-8). Genetic testing should be offered when
an individual has a family history suggesting a genetic
cancer susceptibility condition (5). Several states simply
mention that family history is a risk factor for specific can-
cers, such as breast, colon, and prostate cancer. Other
states dedicate entire sections to family history and call for
educating providers about its use in cancer risk assess-
ment and training them to detect patterns of inheritance
and differentiating hereditary syndromes. Family history
is a public health application of genomics that could be
implemented more fully into CCC plans through aware-
ness and education efforts.
In its 2003 annual report, the CDC identified the pre-
mature commercialization of genetic tests — before
safety, efficacy, and cost-effectiveness had been estab-
lished — as one of the key issues in genetic testing (9).
The year 2003 brought the first direct-to-consumer
advertising for an inherited breast and ovarian cancer
susceptibility genetic test (BRCA1 and BRCA2). Given
this recent development, it is not surprising that none
of the reviewed plans discussed the impact of commer-
cialization of genetic testing and direct-to-consumer
marketing for genetic susceptibility tests. As technology
advances and more tests are available to the public,
there will likely be an increase in this type of marketing
activity by commercial entities. This development 
highlights the increasing importance of providing 
education about informed uses of genetic testing as it
relates to cancer.
Some states (approximately one third) identified reasons
for success in implementation of the genomic components
of their state plans. Predominantly, these included secur-
ing adequate funding, developing excellent partnerships,
and having genetics deemed a high priority within the
state health department. Two states noted that the
resources within the states, such as having staff dedicated
to public health genomics, increased the likelihood of suc-
cessful implementation. As expected, the primary barriers
to successful implementation of the genomic components
were lack of funding and competing priorities. Almost 90%
of states (14/16) interviewed were interested in 
obtaining additional genomics-related training and/or
technical assistance.
In summary, the number of states incorporating genom-
ic components into their CCC plans is increasing. These
states are beginning to implement these objectives.
Periodic reviews of the successes and barriers related to
implementation of genomic components should continue so
as to document progress and share the lessons learned
from these experiences.
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Tables
Table 1. Summary of Genomics-related Themes Among 18
State Comprehensive Cancer Control (CCC) Plans
Used term “genomics”a 1 (5.6)
Used term “genetics”b 17 (94.4)
Discussed “family history”c 17 (94.4)
Discussed training health care professionals 
to use family history for cancer risk assessmentd 6 (33.3)
Discussed providing general education for 
health care providerse 10 (55.6)
Discussed providing general education for publicf 8 (44.4)
Discussed monitoring ongoing research and advancesg 9 (50.0)
Discussed gene–environment interactionsh 5 (27.8)
aPlan mentioned “genomics” in any context. 
bPlan used the term “genetic” or “genetics” in any context. 
cPlan discussed “family history” as related to cancer, most often stated as
a risk factor for cancer. 
dPlan specifically discussed training any health care providers to use family
history as a tool for assessing risk. 
ePlan mentioned providing some form of education for any type of health
care providers about cancer genetics. 
fPlan mentioned providing some form of general education for the public
about cancer genetics, genetic predisposition for cancer, or the importance
of genetic markers. 
gPlan mentioned monitoring ongoing research/advances in cancer genetics,
the field of genetics, or ethical, legal, and social implications of cancer
genetics. 
hPlan mentioned gene–environment interactions as related to cancer.
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No. Plans 
Theme (%)Table 2. Profile of 16 State Comprehensive Cancer Control (CCC) Plans with Genomics Components
Type of Grant
Planning 3 (18.8)
Implementation 13 (81.2)
Have begun to put genomic components of plan into action 9 (56.2)
Have begun to draft a new CCC plan 9 (56.2)
Provided general public education about genomics 4 (25.0)
Provided health care provider education about genomics 7 (43.8)
Perceived priority level of genomics within the state health department
High priority 5 (31.2)
Somewhat a priority 9 (56.2)
Somewhat not a priority 2 (12.5)
Not a priority 0 (0)
Table 3. Identified Successes With and Barriers to Implementation of State Comprehensive Cancer Control (CCC) Plansa
Excellent partnerships and strong 5 (31.2) Lack sufficient funding 6 (37.5)
research/medical community in state
High priority 3 (18.8) Misperceptions/misinformation 4 (25.0)
among public about genomics
Genetic counselor on staff 2 (12.5) Lack of sufficient staff/leadership 3 (18.8)
Additional funding sources 2 (12.5) Low priority 3 (18.8)
Provide continuing credits for professionals  2 (12.5) Time constraints 2 (12.5)
(i.e., CMEs, CEUs)
Lack model/template to apply genetics 2 (12.5)
aA state could report more than one success and/or barrier; percentages are based on 16 plans.
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Have you had a chance to read through the fact sheet we mailed
to you?
_______no (read through and review contents of the fact sheet)
_______yes
Do you have any questions at this point?
_____no
_____yes (resolve/answer questions)
Do you agree to participate in this study?
_____no (stop interview)
_____yes (continue with interview)
Thank you. On behalf of NCCGPH, we are grateful that you have
agreed to participate in this study of genomics content in your
state’s Comprehensive Cancer Control plan. This interview should
take about 45 minutes of your time. I would like to remind you
that the following questions refer to the genomics components of
your CCC plan and not to other activities. Upon completion of the
interview, a written summary of your interview will be sent to you
for verification and approval.
Do I have your permission to audiotape this interview to facilitate
accurate recording of your answers?
_____no (do not turn on the tape recorder)
_____yes
Let’s begin.
1. Have you had a chance to review the materials we sent you
about your cancer plan?
_____no (reschedule the interview)
_____yes
If yes, are there any sections in your plan relating to
genetics/genomics that were missed or that are inaccurate in our
review? If so, please describe these sections.
Do you have any additional comments regarding the review?
2. What type of grant does your state have for CCC development?
_____planning
_____implementation
_____other (specify ______________________)
3. Who was involved in writing the genetics/genomics sections of
your CCC plan?
What is their background as it relates to genetics?
How were these individuals selected?
4. How long did the writing process take for the genetic sections?
What was the general process/procedure used to write the genetic
sections?
5. To date, have you had the opportunity to implement the genetic
components within your action plans?
_____no (go to 6)
_____yes
If yes, what has been accomplished thus far?
If you have begun to implement the genetic components detailed
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Table 4. Training and Technical Assistance Needs in Genomics of 16 States with Genomics Components of Comprehensive
Cancer Control Plan
States requesting training 14 (87.5)
Preferred topicsa
Basic public health genomics concepts 11 (68.8)
Genomics vs genetics defined 4 (25.0)
ELSIb 3 (18.8)
“How to” guide for implementation of genomics components 6 (37.5)
States requesting technical assistance 6 (37.5)
Program planning, implementation, and evaluation services 5 (31.3)
aStates may have responded with more than one training topic; percentages are based on 16 state plans. 
bELSI = ethical, legal, and social implications.
Appendix: Questions for State CCC Plan Interviews
No. (%)in your state plan, how have you been successful in your imple-
mentation? Please explain.
6. If you have begun to implement the genetic components
detailed in your state plan, have you encountered any barriers?
_____no (go to 7)
_____yes
If yes, please explain.
7. Have you provided any activities or programs to educate the
public about genetics and cancer?
_____no (go to 8)
_____yes
If yes, please list or describe these activities or programs.
Using the following 4-point scale where 1 = received positively, 2
= somewhat positively, 3 = somewhat not positively, or 4 = not
positively at all, how have the activities or programs been
received? Received positively, somewhat positively, somewhat not
positively, or not positively at all?
Why do you think these results were obtained?
8. Have you provided any activities or programs to educate health
care providers about genetics and cancer?
_____no (go to 9)
_____yes
If yes, please list or describe these activities or programs.
On the same 4-point scale, how have these activities or programs
been received: received positively, somewhat positively, somewhat
not positively, or not positively at all?
Why do you think these results were obtained?
9. Please rank genomics in terms of priority level for your state
health department on the 4-point scale, where 1 = high priority, 2
= somewhat a priority, 3 = somewhat not a priority and 4 = not a
priority. Is genomics a priority, somewhat of a priority, somewhat
not a priority, or not a priority?
Explain your answer.
10. Have you begun the process of drafting a subsequent CCC
plan?
_____no (go to 11)
_____yes
If yes, has the genomics components changed?
_____no
_____yes
_____not sure — plan not completed
Why or why not?
What is the planned date of issue for the new CCC plan?
Is it an implementation grant?
_____yes
_____no (if no, specify what the type)
11. Does your state have genetic nondiscrimination legislation in
place currently?
_____no
_____yes
_____don’t know
12. As you move forward, what types of partnerships would be
helpful to you in implementing the genomics components of your
state plan?
13. Do you or your staff need additional training in genomics to
assist in implementation of the genetic components of your state
plan?
_____no (go to 14)
_____yes
_____not sure
If yes, what specific topics would you need training in to assist in
implementation of the genetic components of your state plan?
Which of the following training formats would you most prefer?
_____Interactive videoconference
_____CD-ROM (interactive)
_____Phone conference call
_____Internet accessible
_____Standard videotape (not interactive)
14. Are you aware of the currently funded resources available to
you through the three national genomic centers funded by the
CDC?
_____yes (end interview)
_____no
_____not sure
If not, interviewer should explain services.
Would these types of services be of use to you?
_____no (end interview)
_____yes
_____not sure
What type of partnership with the genomic centers would be the
most feasible?
Follow up with asking specifics that they would like or need help
with.
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Thank you very much for your time today. Do you have any ques-
tions for me? I’ll be sending you a summary of our interview for
you to review and approve. Where should I send this?
Record Address:
_______________________________________
Interviewer Signature
_______________________________________
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